NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has come to a restructured research and license agreement with Ramot at Tel Aviv University with respect to payment obligations for its technology license, and that the Double U Fund, a lender to the Company, has also come to an agreement over funds owed to it by BrainStorm. The waiver and release from Ramot ensures that BrainStorm’s technology license is securely held by BrainStorm, and the resolution to the Double U Fund debt obligation improves BrainStorm’s financial condition.
